Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702155 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
A Phase 1 study, sponsored by Delta-Fly Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01702155 is a Phase 1 study that has completed, run by Delta-Fly Pharma. The registered enrollment target is 69 participants.
The verdict
NCT01702155, a Phase 1 study, has completed, sponsored by Delta-Fly Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).
Interventions
- DRUG DFP-10917
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2012-10-10 |
| Est. Completion | 2017-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702155
The ClinicalTrials.gov registry entry for NCT01702155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delta-Fly Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DFP-10917 is the first listed.
NCT01702155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01702155 about?
NCT01702155 is a clinical study titled "Phase I/II Study of DFP-10917 in Patients With Acute Leukemia". The purpose of this study is to determine the safety and efficacy of DFP-10917 given via continuous 7 or 14 day infusion to patients with acute leukemias (AML or ALL).
What is the current status of trial NCT01702155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2012-10-10. Estimated completion is 2017-10-11.
What interventions are being tested in trial NCT01702155?
The interventions under investigation include: DFP-10917 (DRUG).
Who is sponsoring clinical trial NCT01702155?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.